Tscan Therapeutics Inc (TCRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.89M
Last updated: Nov 17, 2026 at 11:05 AM ET
Tscan Therapeutics Inc (TCRX) Earnings: Report Dates and Results
Tscan Therapeutics (TCRX) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Tscan Therapeutics reported EPS of -$0.25, below the -$0.18 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TCRX has an expected report date of Mar 2, 2027.
Earnings History
Of the 23 quarters below that had an estimate, TCRX beat 13, missed 9 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $586000, down 76.7% from $2.51M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.25 | -$0.18 | -$0.23 - -$0.08 | -38.89% | Miss | N/A | 4 | 2 up, 2 down | Nov 12, 2026 | $586000 |
| Jun 30, 2026 | -$0.23 | -$0.29 | N/A | +20.69% | Beat | N/A | 4 | 0 up, 4 down | Aug 12, 2026 | $1.05M |
| Mar 31, 2026 | -$0.22 | -$0.16 | -$0.18 - -$0.13 | -37.50% | Miss | N/A | 4 | 3 up, 0 down | May 6, 2026 | $982000 |
| Dec 31, 2025 | -$0.18 | -$0.27 | -$0.42 - -$0.19 | +32.61% | Beat | N/A | 5 | 1 up, 2 down | Mar 4, 2026 | $2.57M |
| Sep 30, 2025 | -$0.28 | -$0.33 | -$0.57 - -$0.24 | +15.15% | Beat | N/A | 6 | 1 up, 1 down | Nov 12, 2025 | $2.51M |
| Jun 30, 2025 | -$0.28 | -$0.32 | -$0.58 - -$0.22 | +12.50% | Beat | N/A | 6 | 2 up, 1 down | Aug 12, 2025 | $3.08M |
| Mar 31, 2025 | -$0.26 | -$0.28 | -$0.32 - -$0.21 | +7.14% | Beat | N/A | 5 | 1 up, 0 down | May 6, 2025 | $2.17M |
| Dec 31, 2024 | -$0.30 | -$0.29 | -$0.30 - -$0.24 | -3.45% | Miss | N/A | 5 | 2 up, 0 down | Mar 5, 2025 | $665000 |
| Sep 30, 2024 | -$0.25 | -$0.29 | -$0.34 - -$0.24 | +13.79% | Beat | N/A | 7 | 0 up, 0 down | Nov 12, 2024 | $1.05M |
| Jun 30, 2024 | -$0.28 | -$0.28 | -$0.35 - -$0.23 | 0.00% | In line | N/A | 7 | 0 up, 0 down | Aug 12, 2024 | $536000 |
| Mar 31, 2024 | -$0.32 | -$0.24 | -$0.27 - -$0.24 | -33.33% | Miss | N/A | 4 | 0 up, 0 down | May 13, 2024 | $566000 |
| Dec 31, 2023 | -$0.21 | -$0.29 | -$0.44 - -$0.26 | +27.59% | Beat | N/A | 6 | 0 up, 0 down | Mar 6, 2024 | $7.21M |
| Sep 30, 2023 | -$0.24 | -$0.44 | -$0.54 - -$0.25 | +45.45% | Beat | N/A | 5 | 0 up, 0 down | Nov 9, 2023 | $3.89M |
| Jun 30, 2023 | -$0.51 | -$0.78 | -$1.04 - -$0.27 | +34.62% | Beat | N/A | 4 | 1 up, 0 down | Aug 10, 2023 | $3.15M |
| Mar 31, 2023 | -$0.93 | -$0.75 | -$0.80 - -$0.69 | -24.00% | Miss | N/A | 4 | 0 up, 0 down | May 10, 2023 | $6.80M |
| Dec 31, 2022 | -$0.78 | -$0.70 | -$0.80 - -$0.63 | -11.43% | Miss | N/A | 4 | 0 up, 0 down | Mar 8, 2023 | $3.10M |
| Sep 30, 2022 | -$0.67 | -$0.71 | -$0.80 - -$0.65 | +5.63% | Beat | N/A | 4 | 0 up, 0 down | Nov 9, 2022 | $3.36M |
| Jun 30, 2022 | -$0.63 | -$0.72 | N/A | +12.50% | Beat | N/A | N/A | 0 up, 0 down | Aug 10, 2022 | $4.06M |
| Mar 31, 2022 | -$0.67 | -$0.62 | -$0.90 - -$0.57 | -8.06% | Miss | N/A | 4 | 0 up, 0 down | May 9, 2022 | $3.02M |
| Dec 31, 2021 | -$0.38 | -$0.73 | -$0.86 - -$0.60 | +47.95% | Beat | N/A | 5 | N/A | Mar 9, 2022 | $2.85M |
| Sep 30, 2021 | -$0.80 | -$0.48 | -$0.96 - -$0.37 | -66.67% | Miss | N/A | 2 | 1 up, 0 down | Nov 10, 2021 | $2.41M |
| Jun 30, 2021 | -$7.69 | -$4.09 | N/A | -88.02% | Miss | N/A | N/A | N/A | Jul 15, 2021 | $2.85M |
| Mar 31, 2021 | -$1.11 | -$6.40 | N/A | +82.66% | Beat | N/A | N/A | N/A | Apr 30, 2021 | $2.03M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.00, after -$1.15 the year before. It was -$9.98 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.00 | N/A |
| Dec 31, 2024 | -$1.15 | N/A |
| Dec 31, 2023 | -$1.89 | N/A |
| Dec 31, 2022 | -$2.75 | N/A |
| Dec 31, 2021 | -$9.98 | N/A |
Frequently Asked Questions About TCRX
When is Tscan Therapeutics's next earnings date?
Tscan Therapeutics's next earnings report is expected for Mar 2, 2027.
Did TCRX beat earnings estimates last quarter?
No. Tscan Therapeutics reported EPS of -$0.25 for the quarter ended Sep 30, 2026, below the -$0.18 estimate by 38.89%.
What EPS do analysts expect from TCRX next quarter?
The consensus EPS estimate for Tscan Therapeutics for the quarter ending Dec 31, 2026 is -$0.17 from 6 analysts, with estimates from -$0.21 to -$0.09.
How often does TCRX beat earnings estimates?
Tscan Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +1.03%.
TCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors